Moderna has revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Spikevax, its updated COVID-19 vaccine.
Moderna will explore next generation technologies - including quantum computing and artificial intelligence - to advance and accelerate mRNA research via a new partnership with IBM.
An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.
Moderna has announced new mRNA vaccine development programs: with the Lyme disease candidate representing an expansion of the company's mRNA tech to target bacterial pathogens.
The company finalizes a deal to establish its first manufacturing facility in Africa, which will have the capacity to produce 500 million vaccine doses per year.
mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...
Moderna will expand in the US with new offices in San Francisco and Seattle: while the company also expects to hire around 2,000 new employees globally this year.
Moderna’s RSV vaccine launch – expected either late this year or early in 2024 – will draw on the infrastructure and learnings gained from the company's COVID-19 vaccine launch.
The Boston-based messenger RNA (mRNA) specialist Moderna revealed $19.3bn in revenues last year, but rising costs and falling demand for its COVID-19 vaccine cut into its earnings in the fourth quarter of 2022.
The messenger RNA (mRNA) specialist Moderna has teamed up with ElevateBio-owned Life Edit Therapeutics to develop gene editing therapies that are delivered into patients in vivo.
mRNA therapeutics have received increased amounts of attention and funding ever since mRNA vaccines proved effective in curbing the spread of the COVID-19 pandemic. Now, researchers are exploring mRNA therapeutics’ use in other disease spaces, reports...
Phase 3 interim data showed the mRNA vaccine candidate generated a strong immune response against Influenza A; but failed to demonstrate it was at least as effective as an existing vaccine against Influenza B.
US contract development and manufacturing organization, Catalent, reported results today for the second quarter of fiscal 2023, which ended December 31, 2022.
The candidate reported efficacy of 83.7% against RSV-associated lower respiratory tract disease: with Moderna set to file for regulatory approval for the vaccine within the first half of this year.
Moderna and CytomX Therapeutics have announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies using Moderna's mRNA technologies and CytomX's Probody therapeutic platform.
Merck has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PVC) with Moderna following 'significant progress' made by the two companies in the field to date.
The US regulator has given the green light for the distribution of doses of Moderna's COVID-19 booster shots from a manufacturing plant in Indiana run by Catalent.
The US regulator has granted emergency authorization for Pfizer-BioNTech’s and Moderna’s Covid booster shots that target the highly contagious BA.5 omicron subvariant.
The first Omicron bivalent COVID-19 vaccine has been authorized: with the UK’s regulatory agency giving the green light to Moderna’s Spikevax Bivalent Original/Omicron booster shot.
Moderna and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to establish a partnership for vaccine research and development.
Moderna has dosed the first participant in a Phase 1 trial of its Nipah virus vaccine candidate, mRNA-1215, that has been developed in collaboration with the US National Institutes of Health (NIH).
Moderna’s bivalent COVID-19 booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to the original mRNA-1273 booster dose against all variants of concern, including Omicron, according to data released by the company...
Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.
Moderna announced a new supply agreement with the Swiss federal government today for seven million doses of its COVID-19 booster vaccine for anticipated delivery in 2023.
mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.
mRNA pioneer Moderna will establish an Enterprise Solutions Hub in Atlanta: which will host finance, human resources, procurement and digital functions.
Moderna and Thermo Fisher Scientific have announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing of COVID-19 vaccine Spikevax in the US, as well as other investigational mRNA vaccines and therapies.
Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.
Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.
The US biotech says it will establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.
A booster shot of Moderna’s COVID-19 vaccine increases neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels, according to data released by the company today.
Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.
Moderna released what it deemed to be positive interim data from the phase 1 study of its quadrivalent flu vaccine, mRNA-1010, on Friday. But the markets were left underwhelmed.
